Table 1. Baseline patient characteristics and univariate analysis for TTR and OS in patients treated with 5-FU-based chemotherapy (N=391) and in patients with surgery alone (N=208).
| Parameter |
Patients with adjuvant chemotherapy (N=391) |
Patients with surgery alone (N=208) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % |
TTR |
OS |
N | % |
TTR |
OS |
|||||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |||||||
| Agea in years | 62 | 11 | 1.02 (1.00–1.04) | 0.022 | 1.03 (1.01–1.05) | 0.003 | 68 | 11 | 1.03 (1.00–1.06) | 0.040 | 1.10 (1.06–1.13) | <0.001 | ||
| Gender | ||||||||||||||
| Male | 215 | 55.0 | 1 (reference) | 0.697 | 1 (reference) | 0.302 | 115 | 55.3 | 1 (reference) | 0.759 | 1 (reference) | 0.600 | ||
| Female | 176 | 45.0 | 0.93 (0.66–1.33) | 0.81 (0.54–1.21) | 93 | 44.7 | 1.08 (0.65–1.82) | 0.88 (0.55–1.42) | ||||||
| Tb | ||||||||||||||
| T1 and T2 | 29 | 7.4 | 1 (reference) | <0.001 | 1 (reference) | <0.001 | 6 | 2.9 | ||||||
| T3 | 261 | 66.8 | 2.92 (0.92–9.25) | 1.97 (0.62–6.30) | 173 | 83.2 | 1 (reference) | 0.019 | 1 (reference) | 0.087 | ||||
| T4 | 101 | 25.8 | 5.67 (1.76–18.3) | 5.80 (1.79–18.79) | 29 | 13.9 | 2.10 (1.13–3.89) | 1.67 (0.93–3.01) | ||||||
| Grade | ||||||||||||||
| G1 and G2 | 257 | 65.7 | 1 (reference) | 0.416 | 1 (reference) | 0.049 | 161 | 77.4 | 1 (reference) | 0.597 | 1 (reference) | 0.065 | ||
| G3 | 134 | 34.3 | 1.16 (0.81–1.67) | 1.49 (1.00–2.22) | 47 | 22.6 | 1.18 (0.64–2.15) | 1.62 (0.97–2.71) | ||||||
| Lymph node involvement | ||||||||||||||
| N0 | 83 | 21.2 | 1 (reference) | <0.001 | 1 (reference) | <0.001 | 154 | 74.0 | 1 (reference) | <0.001 | 1 (reference) | <0.001 | ||
| N1 | 186 | 47.6 | 1.65 (0.91–3.00) | 1.91 (0.95–3.84) | 43 | 20.7 | 2.56 (1.43–4.57) | 2.66 (1.56–4.54) | ||||||
| N2 | 122 | 31.2 | 4.73 (2.65–8.42) | 4.89 (2.49–9.64) | 11 | 5.3 | 6.98 (3.19–15.25) | 6.08 (2.81–13.13) | ||||||
| Clinical stage | ||||||||||||||
| II | 82 | 21.0 | 1 (reference) | 0.001 | 1 (reference) | 0.001 | 153 | 73.6 | 1 (reference) | <0.001 | 1 (reference) | <0.001 | ||
| III | 309 | 79.0 | 2.68 (1.54–4.67) | 2.96 (1.54–5.70) | 55 | 26.4 | 3.14 (1.86–5.29) | 3.14 (1.93–5.09) | ||||||
| No. of resected lymph nodes | ||||||||||||||
| ⩽12 | 47 | 12.0 | 1 (reference) | 0.817 | 1 (reference) | 0.393 | 37 | 17.8 | 1 (reference) | 0.719 | 1 (reference) | 0.532 | ||
| >12 | 344 | 88.0 | 0.94 (0.57–1.57) | 0.80 (0.47–1.34) | 171 | 82.2 | 1.13 (0.57–2.25) | 1.22 (0.65–2.28) | ||||||
| Tumor location | ||||||||||||||
| Left-sided colon | 236 | 60.4 | 1 (reference) | 0.275 | 1 (reference) | 0.115 | 139 | 66.8 | 1 (reference) | 0.137 | 1 (reference) | 0.199 | ||
| Right-sided colon | 155 | 39.6 | 1.22 (0.86–1.73) | 1.38 (0.93–2.04) | 69 | 33.2 | 1.49 (0.88–2.53) | 1.38 (0.84–2.26) | ||||||
| Lymphovascular invasion | ||||||||||||||
| No | 265 | 67.8 | 1 (reference) | 0.022 | 1 (reference) | 0.086 | 170 | 81.7 | 1 (reference) | 0.413 | 1 (reference) | 0.389 | ||
| Yes | 126 | 32.2 | 1.52 (1.06–2.17) | 1.43 (0.95–2.14) | 38 | 18.3 | 1.30 (0.69–2.46) | 1.30 (0.72–2.33) | ||||||
| Vascular invasion | ||||||||||||||
| No | 348 | 89.0 | 1 (reference) | <0.001 | 1 (reference) | 0.006 | 191 | 91.8 | 1 (reference) | 0.014 | 1 (reference) | 0.008 | ||
| Yes | 43 | 11.0 | 2.31 (1.49–3.59) | 2.04 (1.22–3.41) | 17 | 8.2 | 2.45 (1.20–4.98) | 2.40 (1.26–4.58) | ||||||
| Perineural invasionc | ||||||||||||||
| No | 378 | 96.7 | 1 (reference) | 0.003 | 1 (reference) | 0.216 | 206 | 99.0 | ND | ND | ||||
| Yes | 13 | 3.3 | 3.02 (1.48–6.20) | 1.77 (0.72–4.34) | 2 | 1.0 | ||||||||
Abbreviations: HR, hazard ratio; ND, not determined; OS, overall survival; TTR, time to recurrence; 95% CI, 95% confidence interval.
a
Mean (s.d.).
b
For patients with surgery alone T1, T2 and T3 are combined.
c
For patients with surgery alone the analysis was not done (perineural invasion yes N=2).